November 2013 Issue of The Ophthalmologist

One of the most striking aspects of ophthalmology has been the intensity of manufacturers’ stated commitment to innovation.

Analysis of a rich long-term epidemiological dataset reveals that interventions have significantly reduced the probability of open-angle glaucoma-related blindness

Two studies have found a link between long-term usage of contraceptive pills and glaucoma

An iPhone, an app, and a 20 D lens, along with a bit of practice, will get you fundus photographs in a pinch

The AAO are encouraging diabetics to do something to protect their vision: visit their opthalmologist.

Yet more ophthalmology acquisitions and licensing deals were announced this month

Bayer and Regeneron have presented the phase III trial data for aflibercept treatment of myopic choroidal neovascularization

Five questions that must be answered on the causes and consequences of near-sightedness.

If you had VMT or MH and could avoid vitrectomy, you would. Might ocriplasmin let you?

Predicting treatment outcomes manages their expectations and improves your care.

The last decade has seen some great advances, but there's still room for improvement…

Therapies based on stem cell treatments are considered to have tremendous potential in medicine.

Market research requires that you examine three things: customers, the competition and the environment.

Patients need to know what their ophthalmologist actually ‘does’, and what to expect when they are referred.

Expert opinion: infection prevention & treatment in photorefractive surgery patients.

Who should receive ILUVIEN® for the treatment of chronic DME-associated vision impairment

Jim discusses his background, leadership style and his vision for Oraya's future with us.